Literature DB >> 10856388

Time course of functional recovery after coronary artery bypass graft surgery in patients with chronic left ventricular ischemic dysfunction.

J L Vanoverschelde1, C Depré, B L Gerber, M Borgers, W Wijns, A Robert, R Dion, J A Melin.   

Abstract

Chronic left ventricular (LV) ischemic dysfunction, a condition often referred to as myocardial hibernation, is associated in humans with ultrastructural alterations of the myocytes, including the loss of myofilaments and the accumulation of glycogen. Given the severity of these structural changes, contractile function is unlikely to resume immediately upon revascularization. Therefore, the aim of the present study was to assess the time course of functional improvement after successful revascularization as well as its potential structural correlates. We studied 32 patients with coronary disease and chronic LV ischemic dysfunction who underwent bypass surgery. Dynamic positron emission tomography with N-13 ammonia and F-18 deoxyglucose to assess myocardial perfusion and glucose metabolism was performed in 29 patients. In all patients, a transmural biopsy was harvested from the center of the dysfunctional area, to quantify the increase in extracellular matrix and the presence of structurally altered cardiomyocytes. LV function was serially measured by digitized 2-dimensional echocardiography before and at 10 days, 2 months, and 6 months after revascularization. The time course of recovery of regional function was estimated from the monoexponential decrease in dysfunctional wall motion score. At follow-up, 19 patients had improved LV function, whereas 13 patients showed persistent dysfunction. Before revascularization, reversibly dysfunctional segments had higher myocardial blood flow (82 +/- 29 vs 53 +/- 21 ml. (min. 100 g)(-1), p = 0.044), higher glucose uptake (40 +/- 16 vs 21 +/- 9 micromol. (min. 100 g)(-1), p = 0.001), and less increase in extracellular matrix (25 +/- 15% vs 46 +/- 17%, p = 0.0008) than segments with persistent dysfunction. The extent to which function recovered was positively correlated with myocardial blood flow and negatively correlated with the increase in the extracellular matrix. In patients with reversible dysfunction, the return of segmental function was progressive and followed a monoexponential time course with a median time constant of 23 days (range 6 to 78). The rate of recovery correlated best with the proportion of altered cardiomyocytes in the biopsy. The present study thus indicates that the recovery of regional and global LV function after successful revascularization is progressive and follows a monoexponential time course that is influenced by the extent of the structural changes affecting cardiomyocytes.

Entities:  

Mesh:

Year:  2000        PMID: 10856388     DOI: 10.1016/s0002-9149(00)00790-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  32 in total

1.  Hibernating myocardium: a mitochondrial adaptation that may be destined to heart failure.

Authors:  Sabu Thomas; Edward O McFalls
Journal:  J Cardiovasc Transl Res       Date:  2008-10-17       Impact factor: 4.132

Review 2.  Clinical assessment of myocardial hibernation.

Authors:  Arend F L Schinkel; Jeroen J Bax; Don Poldermans
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

Review 3.  Imaging techniques in nuclear cardiology for the assessment of myocardial viability.

Authors:  Riemer H J A Slart; Jeroen J Bax; Dirk J van Veldhuisen; Ernst E van der Wall; Rudi A J O Dierckx; Pieter L Jager
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-13       Impact factor: 2.357

4.  Improvement of stress LVEF rather than rest LVEF after coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium.

Authors:  V Rizzello; D Poldermans; E Biagini; A F L Schinkel; R van Domburg; A Elhendy; E C Vourvouri; M Bountioukos; A Lombardo; B Krenning; J R T C Roelandt; J J Bax
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

5.  Recovery of impaired microvascular function in collateral dependent myocardium after recanalisation of a chronic total coronary occlusion.

Authors:  G S Werner; U Emig; P Bahrmann; M Ferrari; H R Figulla
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

6.  11C-meta-hydroxyephedrine defects persist despite functional improvement in hibernating myocardium.

Authors:  James A Fallavollita; Michael D Banas; Gen Suzuki; Robert A deKemp; Munawwar Sajjad; John M Canty
Journal:  J Nucl Cardiol       Date:  2009-11-10       Impact factor: 5.952

7.  Time course of functional recovery after coronary artery bypass grafting surgery according to the preoperative reversibility of perfusion impairment on myocardial SPECT.

Authors:  Jin Chul Paeng; Dong Soo Lee; Won Jun Kang; Byeong Il Lee; Ki-Bong Kim; June-Key Chung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-18       Impact factor: 9.236

8.  Minimally invasive system to reliably characterize ventricular electrophysiology from living donors.

Authors:  Aida Oliván-Viguera; María Pérez-Zabalza; Laura García-Mendívil; Konstantinos A Mountris; Sofía Orós-Rodrigo; Estel Ramos-Marquès; José María Vallejo-Gil; Pedro Carlos Fresneda-Roldán; Javier Fañanás-Mastral; Manuel Vázquez-Sancho; Marta Matamala-Adell; Fernando Sorribas-Berjón; Javier André Bellido-Morales; Francisco Javier Mancebón-Sierra; Alexánder Sebastián Vaca-Núñez; Carlos Ballester-Cuenca; Miguel Ángel Marigil; Cristina Pastor; Laura Ordovás; Ralf Köhler; Emiliano Diez; Esther Pueyo
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

9.  Surgical ventricular restoration: an operation to reverse remodeling - the basic science (part I).

Authors:  Ganesh Shanmugam; Imtiaz S Ali
Journal:  Curr Cardiol Rev       Date:  2009-11

10.  Chronic non-transmural infarction has a delayed recovery of function following revascularization.

Authors:  Martin Ugander; Peter A Cain; Per Johnsson; John Palmer; Håkan Arheden
Journal:  BMC Cardiovasc Disord       Date:  2010-01-18       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.